Y-mAbs Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q1 2021 to Q2 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
-
Summary
-
Y-mAbs Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q1 2021 to Q2 2024.
- Y-mAbs Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending June 30, 2024 was $22.2M, a 16.1% increase year-over-year.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Growth (%)